Category

BioTalk

Reverse BioTalk – Jeff Galvin, CEO of American Gene Technologies Interviews Rich Bendis, CEO and President of BioHealth Innovation, Inc.

By | BioTalk, News | No Comments

Jeff Galvin, CEO of American Gene Technologies and Rich Bendis, CEO and President of BioHealth Innovation, Inc. have a fireside chat about the rapid evolution of the BioHealth Capital Region.

You can also listen to the audio only version via Apple https://apple.co/37wc6Kk, Google https://bit.ly/2XbLe0v, Spotify https://spoti.fi/3yCWhxE, and TuneIn https://bit.ly/3AqYkoR.

Click here to view the video interview between Jeff and Rich.

On the heels of Silicon Valley’s branding as one of the world’s largest tech hubs, the BioHealth Capital Region aims to brand the DMV region as one of the most prominent BioHealth clusters in the Mid-Atlantic. BioHealth Innovation, Inc. was founded 11 years ago in an effort to drive ideas from labs into markets through innovation-driven economic development organizations and initiatives.

Galvin and Bendis discuss the abundance of opportunities for growth within the region as it is home to a wide variety of research institutions, top scientists, and annual grants. Additionally, they discuss how BioHealth Innovation, Inc. cultivates success for companies within the competitive region.

Click here to view the video interview between Jeff and Rich.

Paul Rennie OBE and Professor Jason Snape Join Rich Bendis on BioTalk

By | BioTalk, News | No Comments

Paul Rennie OBE, Counsellor for Global Issues in the Global Economy Group at the British Embassy, Washington DC, and Professor Jason Snape, Head of Environmental Protection within AstraZeneca’s Global Sustainability Team, join Rich Bendis to Discuss Life Sciences, Climate Change, COP26 – UN Climate Change Conference, and The Race to Zero Campaign.

Listen now via Apple https://apple.co/3ls3EEp, Google https://bit.ly/3liTlSU, Spotify https://spoti.fi/3ylxair, and TuneIn https://bit.ly/3rS9Giz.

Paul Rennie, OBE, is the Counsellor for Global Issues in the Global Economy Group at the British Embassy, Washington DC, leading the UK’s climate and energy, economic and trade, and science and technology networks across the United States. Prior to that, he led the Foreign Office’s strategic transformation programme, focused on delivering a 21st century Diplomatic Service. Paul was born in Edinburgh and educated at George Heriot’s School, before going on to graduate with an MA in Economics and Politics (Edinburgh University) and an MSc in Economics (York University). He joined the Foreign and Commonwealth Office in 2001 as the first of a new group of Diplomatic Service Economists. He has served at the United Nations (New York), Brazil, India and Malaysia, as well as working on secondment to the Cabinet Office and the Department for International Development. In addition to his economic work, Paul speaks five languages (English, French, Dutch, Portuguese and Hindi).

Professor Jason Snape is the Global Head of Environment within AstraZeneca’s Global Sustainability Team. Accountable for delivering AstraZeneca’s global ambitions to drive natural resource reduction (ambition zero carbon, water and waste reduction) and ensure the environmental safety of pharmaceuticals throughout their lifecycle (product environmental stewardship and pharmaceuticals in the environment). Member of the AstraZeneca UK Leadership Team.  Chair of the European Federation of Pharmaceutical Industry Associations (EFPIA), Medicines for Europe, and AESGP working group on the environmental risk assessment of human medicinal products. Recognized scientific leader and opinion former with >6000 citations from approximately 50 publications. Honorary Clinical Professor at the University of Warwick and a Professor of Environmental Engineering at the University of Newcastle.  Member of the University of York’s Environmental Sustainability Advisory Board.  Co-chair the Society of Environmental Toxicology and Chemistry (SETAC) Pharmaceutical Advisory Group.

Click here for the transcript.

Cartesian Therapeutics President & Chief Executive Officer, Murat Kalayoglu, MD, PhD, Returns to BioTalk

By | BioTalk, News | No Comments

Dr. Murat Kalayoglu, President and CEO at Cartesian Therapeutics, provides an update since his last visit on their cell and gene therapies, as well as fundraising successes.

Listen now on Apple https://apple.co/2SuVe2M, Google https://bit.ly/35Uq6wV, Spotify https://spoti.fi/3w3d7nd, or TuneIn https://bit.ly/2U9zYjL

Dr. Murat Kalayoglu is President and CEO at Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology. The company, founded in 2016, with three assets in clinical trials, is the leader in RNA cell therapy with products in development for autoimmune, oncologic and respiratory disorders. Cartesian’s investigational therapies are manufactured at a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. Prior to Cartesian, Dr. Kalayoglu was co-founder and CEO of Topokine, which he led from concept to late-stage clinical trials, followed by a successful sale to Allergan. Dr. Kalayoglu was also co-founder and COO of HealthHonors Corporation, which he led from concept to commercialization, followed by a successful sale to Healthways. Dr. Kalayoglu is a board-certified ophthalmologist who completed his residency and research Fellowship at Harvard, MD/PhD in immunology at the University of Wisconsin-Madison, and MBA from the MIT Sloan School of Management.

Click here for the transcript.

Dr. Laurie E. Locascio, Vice President for Research at both the University of Maryland College Park and Baltimore, Joins Rich Bendis on a New Episode of BioTalk

By | BioTalk, News | No Comments

Dr. Laurie E. Locascio, Vice President for Research at both the University of Maryland College Park and Baltimore, Visits BioTalk to Discuss Her Career, Tech Transfer, and the Two Institutions Working Together

Listen now on Apple https://apple.co/3oZKsNP, Google https://bit.ly/3vpYr1T, Spotify https://spoti.fi/2QZm3vd, and TuneIn https://bit.ly/2RQqs40.

Laurie E. Locascio, Ph.D., is the Vice President for Research at the University of Maryland, College Park and the University of Maryland, Baltimore.

In this role, Dr. Locascio oversees the University of Maryland’s vibrant research and innovation enterprise at these two campuses, which garner a combined $1.1 billion in external research funding each year. Within Locascio’s purview are the development of large interdisciplinary research programs, technology commercialization, innovation and economic development efforts, and strategic partnerships with industry, federal, academic, and nonprofit collaborators. She is a professor in Maryland’s Fischell Department of Bioengineering, and professor (secondary) in the Department of Pharmacology at the University of Maryland School of Medicine.

Dr. Locascio previously worked at the National Institute of Standards and Technology (NIST), most recently as Acting Principal Deputy Director and Associate Director responsible for leading the internal scientific research and laboratory programs across two campuses in Gaithersburg, MD and Boulder, CO.

Locascio received a B.Sc. in chemistry from James Madison University, a M.Sc. in bioengineering from the University of Utah, and a Ph.D. in toxicology from the University of Maryland, Baltimore. As a biomedical researcher, she published more than 100 scientific papers and 12 patents.

Click here to download the transcript.

Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join Rich Bendis on BioTalk

By | BioTalk, News | No Comments

Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join BioTalk to discuss RNA Disease Diagnostics, UM Ventures, and the commercialization of new medical technologies

Listen via Apple http://apple.co/3bsUsda, Google http://bit.ly/38l26Vd , Spotify http://spoti.fi/38kp9zu, and TuneIN http://bit.ly/2MVFqDp.

 

Prof. Dipanjan Pan, MS, Ph.D., is an expert in nanomedicine, molecular imaging, drug delivery, and biosensing. He is presently a tenured Full Professor in Diagnostic Radiology & Nuclear Medicine, Pediatrics and Chemical, Biochemical and Environmental Engineering at the University of Maryland Baltimore School of Medicine and University of Maryland Baltimore County. Prior to moving to Maryland, he was a tenured Associate Professor and Associate Head of the department in Bioengineering and Materials Science and Engineering and Institute of Sustainability in Energy and Environment at the University of Illinois, Urbana-Champaign. He administratively directs the Nanofabrication and Characterization Core at CBOTH and a Director for the Investigational Probe Design Resources in Radiology.

He serves as study section review board member for NIH, CDMRP (DoD), NSF, and multiple review committee member for American Heart Association. In 2016 he received Nanomaterials Letter (NML) Researcher award, in 2017 a Young Innovator Award from Biomedical Engineering Society (BMES), and a Deans Award for Research Excellence in 2018. He is an elected fellow of the Royal Society of Chemistry, a Fellow of the American Heart Association, and an elected fellow of the American College of Cardiology. Professor Pan is an Associate Editor for WIRES Nanomedicine and Nanobiotechnology (Wiley) and an editorial advisory board member of Molecular Pharmaceutics (ACS).

Phil Robilotto, DO, MBA, is director of the technology development and commercialization program, University of Maryland (UM) Ventures, at the University of Maryland, Baltimore (UMB). Since joining UMB In 2012, Dr. Robilotto has grown UMB’s intellectual property, and licensing efforts, launched a new business venture initiative, and started an early-stage investment program that supports UMB start-ups.

Dr. Robilotto has over 20 years of clinical practice and pharmaceutical/biotechnology strategic planning and business development experience, most recently with Celera and DuPont Pharmaceuticals. He has led valuation and planning efforts for technology platforms and clinical-stage products and has successfully developed, negotiated, and executed collaborations across a broad range of life science-based technologies with a variety of commercial partners.

Dr. Robilotto is a licensed physician in the state of Maryland and received his DO from the Chicago College of Osteopathic Medicine. He also holds a BS in Biology from the College of William and Mary and an MBA from Duke University.

Click here to read the transcript.

Conley Jones, Senior Associate at Alexandria Venture Investments, Guests on BioTalk

By | BioTalk, News | No Comments

Alexandria Venture Investments Senior Associate, Conley Jones, virtually sits down with Rich Bendis on BioTalk to discuss Venture Trends, Investment Goals, and their National Footprint

Listen now on Apple http://apple.co/3sCbtaH, Google http://bit.ly/3kG3MgX, Spotify http://spoti.fi/3kKNGmt, and TuneIn http://bit.ly/3uGvJtJ.

Conley Jones is a Senior Associate with Alexandria Real Estate Equities, Inc., and Alexandria Venture Investments, where he helps manage the company’s New York City and Maryland tenant and investment portfolios. Prior to joining Alexandria in 2016, he worked in a number of roles spanning the healthcare and life science sectors, including as a Business Analyst with liquid biopsy company Sevident, a Healthcare Informatics Specialist with Inova Health Systems, and as a post-baccalaureate researcher with Harvard Medical School. Mr. Jones received his BS in Biology from the College of William & Mary and his MEng in Bioengineering from the University of California, Berkeley.

Click here to view the transcript

John Mumm, CEO of Deka BioSciences, joins Rich Bendis on BioTalk

By | BioTalk, News | No Comments

Deka BioSciences CEO, John Mumm, CEO of Deka BioSciences, virtually guests on BioTalk to discuss his history in the BioHealth Capital Region, Precision Medicine, and Funding Strategies.

Listen now via Apple http://apple.co/3aIy6Ew, Google http://bit.ly/3sfEysd, Spotify http://spoti.fi/3aJq8ei, and Tunein http://bit.ly/2Me25ut.

John has spent 24 years researching and developing various technologies associated with IL-10. His work experience included various leadership roles at Anergen, Introgen Therapeutics, Bacterial BarCodes, Schering-Plough, Merck, Targenics, ARMO BioSciences, ACIR BioSciences, and MedImmune/AstraZeneca. John’s primary focus has been on discovery research at the interface between cancer biology and the adaptive immune response. Visit https://www.dekabiosciences.com/ to learn more about them today.

Click here to view the transcript.

New “Virginia Bio-Connect” Statewide Consortium and Scale-Up Initiative Featured on BioTalk

By | BioTalk, News | No Comments

Amy Adams with George Mason University. Nikki Hastings with CvilleBioHub, and John Newby with Virginia Bio join Rich Bendis to discuss the new “Virginia Bio-Connect” statewide consortium and scale-Up initiative.

Listen now via Apple http://apple.co/39ZDl0M, Google http://bit.ly/3iRzmHO, Spotify https://spoti.fi/2MqHTVJ, and TuneIn http://bit.ly/2Yelr58. #innovation #biotalk #university #healthcare #digitalhealth #healthtech #research #biotech

Amy Adams:

As Executive Director of the Institute for Biohealth Innovation, Amy Adams and her team support a talented and innovative research community of faculty and students across multiple disciplines who conduct cutting-edge biomedical and health research. She serves as a point of contact to unite George Mason University (Mason) researchers with the broader community. In addition to research, Amy led outreach efforts and built programs including the Aspiring Scientists Summer Internship Program and the Galileo’s Science Café to engage high school and undergraduate students in research across STEM disciplines, communicate science to the public, and foster internal and external research collaborations. Amy earned a M.S. in Chemistry, and a B.S. in Biology, from George Mason University.

Nikki Hastings:

Nikki Hastings is the executive director of CvilleBioHub in Charlottesville, Virginia working to strengthen and grow the regional biotechnology industry ecosystem. Over the past decade, she has contributed to the growth of early-stage companies including HemoShear Therapeutics and Contraline by leading operational and growth needs and supporting the translation of research concepts into commercial viability. Nikki holds a Ph.D. in biomedical engineering from the University of Virginia and a B.S. from North Carolina State University in the same field.

John Newby:

John Newby is the CEO at Virginia Bio, the statewide non-profit trade association for the life science industry. Approximately 300 companies spanning biopharmaceuticals, medical devices, med tech, diagnostics, digital health, bioinformatics, agriculture, and industrial bio and related fields are based in Virginia, mainly clustered around research universities and medical institutions. Virginia Bio is the sole state affiliate and works closely with key national industry organizations BIO, AdvaMed, MDMA, PhRMA and We Work for Health. Newby previously commanded an Air Force special operations unit supporting the U.S. Army’s 3rd and 7th Special Forces Groups (Airborne), and served in Iraq as an aviator aboard the Boeing B-1B Lancer strategic bomber. Newby received a B.S. from the United States Air Force Academy, with Military Distinction, and his J.D. from the University of Virginia School of Law.

Click here to download the transcript.

United States Pharmacopeia CEO Ronald T. Piervincenzi, Ph.D. Joins Rich Bendis on the BioTalk Podcast

By | BioTalk, News | No Comments

Ronald T. Piervincenzi, Ph.D., Chief Executive Officer, United States Pharmacopeia virtually sits down with Rich Bendis to discuss the over 200 year old Organization, the services they offer, and their goals for the future.

Listen now on Google http://bit.ly/2NjX8As, Apple http://apple.co/3irukRQ, Spotify http://spoti.fi/35UfM8B, and TuneIn http://bit.ly/2XRFEgD.

Ronald T. Piervincenzi, Ph.D., has served as Chief Executive Officer of the United States Pharmacopeia since February 2014. Dr. Piervincenzi provides strategic leadership to USP’s global staff of over 1,400 across sites in Rockville/USA, Brazil, China, Ghana, and India. His transformative vision has launched key USP initiatives in bringing quality across the healthcare spectrum, upholding USP’s reputation as a quality leader since its founding in 1820. Under his leadership, USP has modernized its operations and launched innovative new science, including in the areas of digital medicine, cutting-edge manufacturing technologies and advanced biologics. USP is also better connecting to its stakeholders and customers through new initiatives including the Hyderabad Training Institute in India, the Quality Institute, and USP’s new Impurities for Development service. Dr. Piervincenzi also provides oversight and leadership of USP’s global public health initiatives, including sites in Ethiopia, Indonesia, Nigeria and the Philippines. Dr. Piervincenzi served as Chair of the Council of Experts, USP’s scientific standards-setting body of 24 Expert Committees and over 750 standards-setting experts until June 2015, when he transferred this responsibility to USP’s new Chief Science Officer.

Dr. Piervincenzi brings more than 20 years of industry experience across pharmaceutical sciences, research and business strategy. Before joining USP, Dr. Piervincenzi served as Vice President of Development Sciences with Biogen Idec, Inc., where he designed and launched Biogen’s value-based medicine group focusing on applying tools and technologies of personalized medicine in the treatment and management of multiple sclerosis. Dr. Piervincenzi was a partner and leader in McKinsey & Company’s global pharmaceutical and medical products practice for over 12 years. In this capacity, Dr. Piervincenzi launched McKinsey’s global drug safety, medical and regulatory service line. With McKinsey, Dr. Piervincenzi also led the global research and information analytics team, managing staff in New Jersey, London, Brussels, and India.

Dr. Piervincenzi earned his M.S. and Ph.D. from Duke University in Biomedical Engineering, with research focused on protein engineering. He is the proud co-founder and chairman of the board for the Newark Mentoring Movement.

Click here for the transcript.

Chris Mathia, Chief Executive Officer, Innara Health, and Keith Molzer, Managing Partner, Flyover Capital, join Rich Bendis from Kansas City on BioTalk

By | BioTalk, News | No Comments

While home in Kansas City for the season, BioTalk host Rich Bendis virtually sits down two local business leaders. Innar Health CEO, Chris Mathia, and Flyover Capital Managing Partner, Keith Molzer chat about the opportunities and challenges of BioHealth and Fund-Raising in Middle American.

Listen now via Google http://bit.ly/39ikNss, Apple http://apple.co/3shRRtk, Spotify http://spoti.fi/39ocgUz, and TuneIn http://bit.ly/2XvT0za.

A Kansas City, Kansas native, Chris Mathia joined Innara Health as Vice President of Sales in October of 2017. He was promoted to Chief Executive Officer in May of 2019 and brings 20+ years of healthcare sales and leadership experience to the Innara team. Throughout his career, he has focused on building client confidence, improving the client experience, and increasing overall client satisfaction and reference ability.

Prior to joining Innara, Chris served in various sales and leadership roles with Perceptive/Hyland Software, Cerner Corporation, Thompson Reuters, and Medline Industries. Chris received his bachelor’s degree in Political Science from the University of Kansas.

From working on his grandparent’s farm in Nebraska to becoming a serial entrepreneur, getting his hands dirty is in Keith’s DNA.   Keith has been an entrepreneur for more than 35 years, starting a variety of companies in the Kansas City region.

Prior to co-founding Flyover Capital in 2014, Keith Molzer founded Balance Innovations in 2004 and built the company into the leading developer of cash office software solutions for the retail industry (acquired by Brinks). Prior to founding Balance Innovations, Keith founded in worked with several other start-ups including Entrepreneurial Consulting Corporation which advised clients within technology, economic development agencies, state, and federal government agencies. Clients included the Kauffman Foundation, KTEC, NIST/ATP, KCCatalyst, and several state entrepreneurial initiatives.

Keith has a passion for supporting entrepreneurship and has spoken as a guest lecturer at Rockhurst University, University of Nebraska, the University of Kansas. Keith has also served as a mentor for KCSpark Lab, KC Pipeline, and the KC Tech Counsel.  Outside of Flyover, Keith is also an active angel investor and has invested in over 15 deals throughout the Midwest. Keith currently serves on the boards of Lending Standard, Innara Health, Inprentus, Verusen, Aker and Layr.  He previously served on the boards of Agrible (acquired by Nutrien), Risk Genius (Acquired by Bold Penguin), and Balance Innovations (acquired by Brinks).

Click here for the transcript.

Join our Mailing List